- Our Products & Expertise
- About Baxter
- Corporate Responsibility
- Contact & Support
It looks like your browser is outdated. For the best experience, please consider updating to the latest version or switching to another browser (Firefox, Chrome, Safari).
As we prepare for the next phase of our journey, we are committed to working on your behalf to build long-term shareholder value in pursuit of our mission.
2015 was a pivotal year for Baxter: In July we executed the spinoff of our BioScience business. The corporate separation created value for investors and resulted in a Baxter portfolio focused solely on the Hospital Products and Renal technologies central to our core identity. Today we are collaborating around the world to shape a leaner, more efficient company, positioned to deliver on our mission and succeed on behalf of all our stakeholders well into the future.View our latest Annual Report
|Data provided by Nasdaq. Minimum 15 minutes delayed.|
Baxter’s Recently Launched SHARESOURCE Telehealth System Has Securely Managed 150,000 Home Dialysis Patient Treatments Globally
New Data Show Malnutrition in U.S. Hospitals Associated with a $42 Billion Burden to Health System
Baxter International Inc. to Host Third Quarter 2016 Financial Results Conference Call for Investors
Analysts, portfolio managers, and current and prospective shareholders seeking additional investor information can contact Clare Trachtman at +1 (224) 948-3085.
Retail shareholder inquires may directed to Baxter Investor Relations at Global_CORP_Investor_Relations@baxter.com.Sign up for email alerts